MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the...

Related Keywords

Germany ,South Africa ,Wellington ,New Zealand General ,New Zealand ,Paris ,France General ,France ,Denmark ,Copenhagen ,Køavn ,United Kingdom ,Danish ,Veronica Gambillara ,Pureos Bioventures ,Christian Thomsen ,Groupb Strep International ,Groupb Streptococcus ,Lund University ,European Union ,European Medicines Agency ,Groupb Strep ,Impact Fund Novo Holdings ,European Investment Bank ,Trill Impact Ventures ,European Investment ,Novo Holdings ,Sunstone Life Science Ventures ,Wellington Partners ,Sanofi Ventures ,Adjuvant Capital ,Chief Executive Officer ,Bita Sehat ,Senior Director ,Senior Investment Director ,Life Science ,Groupb Strep Support ,Impact House ,Trill Impact ,Swiss Based Pureos Partners ,Climate Bank Roadmap ,Innovfin Infectious Diseases Finance Facility ,Minervax ,